Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Rashid Kolvear, Fariborz ^a,b   Taboski, Michael A S ^a,b,c   Nguyen, Johnny ^a   Wang, Dong Yu ^b   Harrington, Lea A ^a,b,d   Done, Susan J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SHORT HAIRPIN RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; ESR1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; SMALL INTERFERING RNA; TERT PROTEIN, HUMAN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION TERMINATION; BREAST TUMOR; DNA MICROARRAY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CHROMANS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; HYPOGLYCEMIC AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TELOMERASE; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77954763598     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-390     Document Type: Article

References (58)

1. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada PTCR, Canada PHAo Canadian Cancer Statistics. Canadian Cancer Statistics 2008, Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada PTCR, Canada PHAo.
2. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32. 10.1002/cncr.22381, 17146782.
3. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992, 89(21):10114-10118. 10.1073/pnas.89.21.10114, 50288, 1438199.
4. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8(3):167-179. 10.1038/nrc2275, 18256617.
5. Carey LA, Hedican CA, Henderson GS, Umbricht CB, Dome JS, Varon D, Sukumar S. Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers. Clin Cancer Res 1998, 4(2):435-440.
6. Carey LA, Kim NW, Goodman S, Marks J, Henderson G, Umbricht CB, Dome JS, Dooley W, Amshey SR, Sukumar S. Telomerase activity and prognosis in primary breast cancers. J Clin Oncol 1999, 17(10):3075-3081.
7. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33(5):787-791. 10.1016/S0959-8049(97)00062-2, 9282118.
8. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315(5820):1850-1853. 10.1126/science.1138596, 17395830.
9. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997, 17(4):498-502. 10.1038/ng1297-498, 9398860.
10. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993, 32(21):5598-5604. 10.1021/bi00072a015, 7684926.
11. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992, 6(10):1634-1641. 10.1210/me.6.10.1634, 1333051.
12. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 1996, 224(2):431-437. 10.1006/bbrc.1996.1044, 8702406.
13. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007, 11(5):395-406. 10.1016/j.ccr.2007.02.025, 2564847, 17482130.
14. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000, 97(20):10990-10995. 10.1073/pnas.180329197, 27136, 10984506.
15. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999, 3(6):799-804. 10.1016/S1097-2765(01)80012-5, 10394368.
16. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005, 123(6):993-999. 10.1016/j.cell.2005.11.026, 16360030.
17. Jarrar MH, Baranova A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J Cell Mol Med 2007, 11(1):71-87. 10.1111/j.1582-4934.2007.00003.x, 17367502.
18. Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T, Sano H. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001, 287(3):727-732. 10.1006/bbrc.2001.5640, 11563856.
19. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998, 1(3):465-470. 10.1016/S1097-2765(00)80047-7, 9660931.
20. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001, 7(1):41-47. 10.1038/83328, 11135614.
21. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000, 83(10):1394-1400. 10.1054/bjoc.2000.1457, 2408786, 11044367.
22. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997, 94(1):237-241. 10.1073/pnas.94.1.237, 19300, 8990192.
23. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006, 13(2):401-413. 10.1677/erc.1.01182, 16728570.
24. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003, 79(3):391-397. 10.1023/A:1024038127156, 12846423.
25. Choi SH, Kang HK, Im EO, Kim YJ, Bae YT, Choi YH, Lee KH, Chung HY, Chang HK, Kim ND. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by retinoic acids. Int J Oncol 2000, 17(5):971-976.
26. Fink SP, Swinler SE, Lutterbaugh JD, Massague J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK, Markowitz S. Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line. Cancer Res 2001, 61(1):256-260.
27. Kaul D, Anand PK, Khanna A. Functional genomics of PPAR-gamma in human immunomodulatory cells. Mol Cell Biochem 2006, 290(1-2):211-215. 10.1007/s11010-006-9169-8, 16633734.
28. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ Res 2006, 98(7):e50-59. 10.1161/01.RES.0000218271.93076.c3, 16556873.
29. Strakova N, Ehrmann J, Dzubak P, Bouchal J, Kolar Z. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 2004, 309(3):1239-1247. 10.1124/jpet.103.063438, 14988421.
30. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72(11):8463-8471. 110254, 9765382.
31. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93(21):11382-11388. 10.1073/pnas.93.21.11382, 38066, 8876144.
32. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
33. Kim HJ, Kim JY, Meng Z, Wang LH, Liu F, Conrads TP, Burke TR, Veenstra TD, Farrar WL. 15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. Cancer Res 2007, 67(6):2595-2602. 10.1158/0008-5472.CAN-06-3043, 17363578.
34. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000, 275(3):1873-1877. 10.1074/jbc.275.3.1873, 10636887.
35. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997, 124(3):179-192. 10.1016/S0300-483X(97)00151-0, 9482120.
36. Chou FS, Wang PS, Kulp S, Pinzone JJ. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Mol Cancer Res 2007, 5(6):523-530. 10.1158/1541-7786.MCR-06-0278, 17579114.
37. Sharma HW, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, Stein CA, Nichols G, Khaled Z, Telang NT, Narayanan R. Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci USA 1995, 92(26):12343-12346. 10.1073/pnas.92.26.12343, 40353, 8618897.
38. Nakatake M, Kakiuchi Y, Sasaki N, Murakami-Murofushi K, Yamada O. STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle 2007, 6(12):1496-1501.
39. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994, 263(5146):526-529. 10.1126/science.8290962, 8290962.
40. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743. 10.1073/pnas.0409462102, 548329, 15701700.
41. Treeck O, Weber A, Boester M, Porz S, Frey N, Diedrich K, Ortmann O. H-ras dependent estrogenic effects of epidermal growth factor in the estrogen-independent breast cancer cell line MDA-MB-231. Breast Cancer Res Treat 2003, 80(2):155-162. 10.1023/A:1024502107690, 12908818.
42. Liu JJ, Hu T, Wu XY, Wang CZ, Xu Y, Zhang Y, Xiao RZ, Lin DJ, Huang RW, Liu Q. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone--induced apoptosis in leukemia k562 cells and its mechanisms of action. Int J Toxicol 2009, 28(2):123-131. 10.1177/1091581809335312, 19482836.
43. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004, 91(2):305-311. 2409804, 15213724.
44. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K, Koeffler HP. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002, 74(2):155-165. 10.1023/A:1016114026769, 12186376.
45. Yee LD, Guo Y, Bradbury J, Suster S, Clinton SK, Seewaldt VL. The antiproliferative effects of PPARgamma ligands in normal human mammary epithelial cells. Breast Cancer Res Treat 2003, 78(2):179-192. 10.1023/A:1022978608125, 12725418.
46. Murillo-Ortiz B, Astudillo-De la Vega H, Castillo-Medina S, Malacara JM, Benitez-Bribiesca L. Telomerase activity, estrogen receptors (alpha, beta), Bcl-2 expression in human breast cancer and treatment response. BMC Cancer 2006, 6:206. 10.1186/1471-2407-6-206, 1562436, 16911782.
47. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M. Estrogen activates telomerase. Cancer Res 1999, 59(23):5917-5921.
48. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000, 28(3):669-677. 10.1093/nar/28.3.669, 102554, 10637317.
49. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004, 10(20):7022-7030. 10.1158/1078-0432.CCR-04-0879, 15501982.
50. Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, Chapleur Y, Flament S. New troglitazone derivatives devoid of PPARgamma agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res Treat 2010,
51. Kondoh K, Tsuji N, Asanuma K, Kobayashi D, Watanabe N. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-Delta(12,14)-prostaglandin J(2)-induced apoptosis in cancer cells. Exp Cell Res 2007, 313(16):3486-96. 10.1016/j.yexcr.2007.06.028, 17706193.
52. Yang YC, Tsao YP, Ho TC, Choung IP. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 2007, 17(2):418-425. 10.1111/j.1525-1438.2006.00866.x, 17316361.
53. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O, Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006, 11(9):1503-1512. 10.1007/s10495-006-8896-3, 16820965.
54. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005, 65(4):1561-1569. 10.1158/0008-5472.CAN-04-1677, 15735046.
55. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999, 455(1-2):135-139. 10.1016/S0014-5793(99)00871-6, 10428487.
56. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998, 95(15):8806-8811. 10.1073/pnas.95.15.8806, 21158, 9671760.
57. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86(5):2170-2177. 10.1210/jc.86.5.2170, 11344222.
58. Kirkpatrick KL, Clark G, Ghilchick M, Newbold RF, Mokbel K. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 2003, 29(4):321-326. 10.1053/ejso.2002.1374, 12711283.